PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Trial details
- Registry ID
- NCT03993379
- Phase
- Phase 2
The FDA approved Ipilimumab (BMS-734016) on 25 Mar 2011.
Drug identity checked against registry records
Also recorded as BMS-734016; Yervoy
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2011-03-25Day | Ipilimumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125377", "applicant_as_listed_by_fda": "BRISTOL MYERS SQUIBB", "brand_names": ["YERVOY"], "active_ingredients": ["IPILIMUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20110325", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |